Logo 1 Logo 2

Clinical Trial Details

Trial ID: L5811
Source ID: NCT01826370
Associated Drug: Linagliptin
Title: Linagliptin Among Filipino Patients With Type 2 Diabetes Mellitus
Acronym:
Status: TERMINATED
Study Results: YES
Results: https://ClinicalTrials.gov/show/NCT01826370/results
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG: Linagliptin
Outcome Measures: Primary: Frequency of Adverse Events and Serious Adverse Events, Frequency of adverse events and serious adverse events in an actual clinical setting, including hypoglycemic events., Week 24 | Secondary: Change From Baseline to Week 24 of HbA1c, Change from baseline to week 24 of glycosylated hemoglobin (HbA1c), Baseline and 24 weeks|Change From Baseline to Week 24 of Fasting Blood Sugar, Change from baseline to week 24 of fasting blood sugar, Baseline and 24 weeks
Sponsor/Collaborators: Sponsor: Boehringer Ingelheim
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases:
Enrollment: 678
Study Type: OBSERVATIONAL
Study Designs: Observational Model: |Time Perspective: p
Start Date: 2012-05
Completion Date: 2013-10
Results First Posted: 2014-09-18
Last Update Posted: 2014-09-18
Locations: Boehringer Ingelheim Investigational Site 43, Agoo, La Union, Philippines|Boehringer Ingelheim Investigational Site 40, Angeles City, Pampanga, Philippines|Boehringer Ingelheim Investigational Site 31, Angono, Rizal, Philippines|Boehringer Ingelheim Investigational Site 32, Antipolo, Rizal, Philippines|Boehringer Ingelheim Investigational Site 27, Aparri, Cagayan, Philippines|Boehringer Ingelheim Investigational Site 4, Batangas, Philippines|Boehringer Ingelheim Investigational Site 48, Butuan City, Agusan del Norte, Philippines|Boehringer Ingelheim Investigational Site 12, Cabanatuan, Nueva Ecija, Philippines|Boehringer Ingelheim Investigational Site 23, Cagayan de Oro, Philippines|Boehringer Ingelheim Investigational Site 3, Caloocan, Philippines|Boehringer Ingelheim Investigational Site 42, Cardona, Rizal, Philippines|Boehringer Ingelheim Investigational Site 25, Cebu, Philippines|Boehringer Ingelheim Investigational Site 44, Dagupan, Pangasinan, Philippines|Boehringer Ingelheim Investigational Site 49, Iligan City, Lanao del Norte, Philippines|Boehringer Ingelheim Investigational Site 2, Iloilo, Philippines|Boehringer Ingelheim Investigational Site 45, Iriga City, Camarines Sur, Philippines|Boehringer Ingelheim Investigational Site 20, Laoag, Ilocos Norte, Philippines|Boehringer Ingelheim Investigational Site 24, Las Pinas, Philippines|Boehringer Ingelheim Investigational Site 7, Legazpi, Albay, Philippines|Boehringer Ingelheim Investigational Site 35, Lucena, Quezon, Philippines|Boehringer Ingelheim Investigational Site 1, Makati, Philippines|Boehringer Ingelheim Investigational Site 39, Malolos, Bulacan, Philippines|Boehringer Ingelheim Investigational Site 37, Mandaluyong City, Philippines|Boehringer Ingelheim Investigational Site 28, Manila, Philippines|Boehringer Ingelheim Investigational Site 5, Marikina, Philippines|Boehringer Ingelheim Investigational Site 16, Meycauyan, Bulacan, Philippines|Boehringer Ingelheim Investigational Site 47, Naga City, Camarines Sur, Philippines|Boehringer Ingelheim Investigational Site 15, Olongapo, Philippines|Boehringer Ingelheim Investigational Site 10, Pampanga, Philippines|Boehringer Ingelheim Investigational Site 19, Paranaque, Philippines|Boehringer Ingelheim Investigational Site 51, Pasay City, Philippines|Boehringer Ingelheim Investigational Site 30, Pasig, Philippines|Boehringer Ingelheim Investigational Site 34, Puerto Princesa, Palawan, Philippines|Boehringer Ingelheim Investigational Site 26, Quezon City, Philippines|Boehringer Ingelheim Investigational Site 11, Rosales, Pangasinan, Philippines|Boehringer Ingelheim Investigational Site 21, San Fernando, La Union, Philippines|Boehringer Ingelheim Investigational Site 9, San Fernando, Pampanga, Philippines|Boehringer Ingelheim Investigational Site 13, San Jose, Nueva Ecija, Philippines|Boehringer Ingelheim Investigational Site 29, San Juan, Philippines|Boehringer Ingelheim Investigational Site 8, San Pablo, Laguna, Philippines|Boehringer Ingelheim Investigational Site 50, San Pedro, Laguna, Philippines|Boehringer Ingelheim Investigational Site 41, Santiago city, Isabela, Philippines|Boehringer Ingelheim Investigational Site 36, Sogod, Southern Leyte, Philippines|Boehringer Ingelheim Investigational Site 38, Sta.Maria, Bulacan, Philippines|Boehringer Ingelheim Investigational Site 6, Tacloban, Philippines|Boehringer Ingelheim Investigational Site 33, Tagbilaran, Bohol, Philippines|Boehringer Ingelheim Investigational Site 14, Tuguegarao, Cagayan, Philippines|Boehringer Ingelheim Investigational Site 18, Urdaneta, Pangasinan, Philippines|Boehringer Ingelheim Investigational Site 46, Valencia City Bukidnon, Philippines|Boehringer Ingelheim Investigational Site 17, Valenzuela, Bulacan, Philippines|Boehringer Ingelheim Investigational Site 22, Zamboanga, Philippines
URL: https://clinicaltrials.gov/show/NCT01826370

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress